×
About 265 results

ALLMedicine™ Papillary Tumors Center

Research & Reviews  90 results

Clear cell and papillary renal cell carcinomas in hereditary papillary renal cell carci...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606058
Diagnostic Pathology; Ferlicot S, Just PA et. al.

Nov 22nd, 2021 - Hereditary papillary renal cell carcinoma (HPRCC) is a rare autosomal dominant disease characterized by the development of multiple and bilateral papillary type I renal cell carcinomas (RCC) and papillary adenomas caused by activating mutations in...

Multiple bronchiolar adenomas with malignant transformation and CCNE1 mutation: a case ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525040
Journal of Cardiothoracic Surgery; Li X, Wu Y et. al.

Oct 20th, 2021 - Bronchiolar adenoma (BA) is a recently proposed diagnostic terminology, which is considered as the expansion of the concept of ciliated muconodular papillary tumors. BA is considered to be a benign neoplasm, but a few previous cases have been repo...

Bronchiolar adenomas (BA) - A detailed radio-pathologic analysis of six cases and revie...
https://doi.org/10.1016/j.anndiagpath.2021.151837
Annals of Diagnostic Pathology; Krishnamurthy K, Kochiyil J et. al.

Oct 10th, 2021 - Bronchiolar adenomas (BAs)/ciliated muco-nodular papillary tumors (CMPTs), are small, peripheral lung nodules arising predominantly in the elderly that follow a benign course. They can be mistaken for adenocarcinomas on frozen section. Immunohisto...

Robot-Assisted Radical Nephroureterectomy.
https://doi.org/10.1089/end.2020.1074
Journal of Endourology; Joseph JP, O'Malley P et. al.

Sep 10th, 2021 - First proposed by Kimball and Ferris in 1933 for the treatment of papillary tumors in the upper urinary tract, radical nephroureterectomy (RNU) with bladder cuff excision remains the gold standard for management of high-risk upper tract urothelial...

Molecular subtyping and immune-gene signatures identify a subset of early bladder tumor...
https://doi.org/10.1016/j.urolonc.2021.06.011
Urologic Oncology; Necchi A, Raggi D et. al.

Jul 25th, 2021 - Clinical high-grade (HG) T1 non-muscle invasive bladder cancer (NMIBC) represents a significant risk to patients, but these patients are not typically offered neoadjuvant therapies, including immune therapy. In this study, we determine whether pat...

see more →

Drugs  1 results see all →

News  15 results

TURBT Plus Nivolumab/Chemo Shows Promise in Muscle-Invasive Bladder Cancer
https://www.onclive.com/view/bladder-sparing-nivolumab-based-strategy-shows-promise-in-mibc

Jun 9th, 2021 - Combining transurethral resection of the bladder tumor (TURBT) with nivolumab (Opdivo) and chemotherapy showed promise as a bladder-sparing treatment strategy in patients with muscle-invasive bladder cancer (MIBC), according to findings from the p...

DTC: Histological Subtypes and Tumor Differentiation
https://www.onclive.com/view/dtc-histological-subtypes-and-tumor-differentiation

Apr 2nd, 2021 - Lori J. Wirth, MD: I agree that one of the interesting things about thyroid cancer is that it’s not a one-size-fits-all operation. There are varying histologies. When we’re thinking about differentiated thyroid cancer, papillary thyroid cancer is ...

FDA Approvals in Urothelial Cancer and GIST, Promising Data in Urothelial Carcinoma, and More
https://www.onclive.com/view/fda-approvals-in-urothelial-cancer-and-gist-promising-data-in-urothelial-carcinoma-and-more

Apr 2nd, 2021 - Today- FDA approvals in urothelial cancer and gastrointestinal stromal tumor, promising results in urothelial carcinoma, mixed findings in small cell lung cancer, disappointing data in graft-versus-host disease, and a partial clinical hold in T...

Persistent BCG Shortages Lead to Hard Choices in Bladder Cancer
https://www.onclive.com/view/persistent-bcg-shortages-lead-to-hard-choices-in-bladder-cancer

Dec 5th, 2020 - Edward Messing, MD Over the years, the Tice strain of bacillus Calmette—Guérin (BCG) has emerged as a go-to drug for treating primary and recurrent bladder cancer, but in the United States and some other countries, a constellation of marketplace ...

FDA Panel Supports Pembrolizumab for High-Risk NMIBC
https://www.onclive.com/view/fda-panel-supports-pembrolizumab-for-highrisk-nmibc

Dec 4th, 2020 - The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 9 to 4 supporting the approval of a new drug application (NDA) for pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)—unresponsive, high-risk, non-mu...

see more →